GlassScriptPhysician profile
William W Shough
NPI 1184060972
$12,797.87
in general payments reported to CMS, 2019-2025
62 companies · $2,252 in 2025
The $2,252 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,387 · 2022: $2,153 · 2023: $2,916 · 2024: $3,090 · 2025: $2,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,257.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,198.62 | 2021-2025 | |
| Novo Nordisk INC | $1,176.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $849.10 | 2021-2025 | |
| Lilly USA, LLC | $779.85 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $749.09 | 2021-2025 | Rexulti, Jynarque, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $627.18 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $530.07 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $465.72 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $376.09 | 2021-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $353.34 | 2021-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.85 | 2021-2025 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $313.59 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.18 | 2021-2025 | Jardiance |
| Abbott Laboratories | $270.24 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $259.79 | 2021-2025 | Spravato |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $253.83 | 2021-2025 | Belsomra, Capvaxive, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $224.75 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $184.52 | 2021-2024 | Eliquis |
| Dexcom, INC. | $176.76 | 2021-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $172.92 | 2021-2024 | Contrave, Onzetra Xsail |
| Biohaven Pharmaceutical Holding Company LTD. | $159.08 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.93 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $140.67 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $128.52 | 2024-2025 | Ibsrela |
| Astellas Pharma US INC | $117.39 | 2021-2024 | Veozah |
| Nestle Healthcare Nutrition INC. | $116.14 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $108.86 | 2024 | |
| Vanda Pharmaceuticals INC. | $106.43 | 2024-2025 | Hetlioz, Fanapt |
| Ironwood Pharmaceuticals, INC | $99.86 | 2021-2024 | Linzess |
| Novartis Pharmaceuticals Corporation | $80.41 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $77.13 | 2021 | |
| Biogen, INC. | $75.24 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $73.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $68.12 | 2021-2023 | |
| Esperion Therapeutics, INC. | $66.23 | 2021 | |
| Eisai INC. | $51.37 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $46.38 | 2022-2023 | Quviviq |
| Seqirus USA INC | $44.99 | 2022-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Alkermes, INC. | $43.18 | 2023 | Lybalvi, Aristada |
| Corium, LLC | $43.06 | 2022-2023 | Adlarity |
| Medtronic, INC. | $40.23 | 2022-2025 | Synchromedii |
| Exact Sciences Corporation | $32.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Impel Pharmaceuticals INC. | $32.53 | 2023 | Trudhesa |
| Xeris Pharmaceuticals, INC. | $31.59 | 2022 | |
| Phadia US INC. | $30.04 | 2024 | Immunocap |
| Amarin Pharma, INC. | $28.47 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $27.71 | 2022-2025 | Zoryve |
| Axonics, INC. | $27.54 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $22.64 | 2025 | Neffy |
| Axsome Therapeutics, INC. | $18.10 | 2024 | Auvelity |
| Lexicon Pharmaceuticals, INC. | $17.52 | 2024 | |
| Insulet Corporation | $17.03 | 2024 | Omnipod |
| Genentech USA, INC. | $16.82 | 2021 | |
| Tandem Diabetes Care, INC. | $16.69 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Organon LLC | $15.90 | 2024 | |
| Kaleo, INC. | $14.21 | 2022 | |
| Sanofi Pasteur INC. | $14.08 | 2023 | |
| Vifor Pharma, INC. | $12.04 | 2021 | |
| Allergan, INC. | $11.87 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.31 | 2023 | Lifevest |
| Supernus Pharmaceuticals, INC. | $11.12 | 2021 | |
| Metacel Pharmaceuticals LLC | $7.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.